Milne Jill C. 4
4 · BIOCRYST PHARMACEUTICALS INC · Filed Jan 27, 2026
Research Summary
AI-generated summary of this filing
BioCryst (BCRX) Director Jill Milne Receives Awards
What Happened
Jill C. Milne, a non-employee director of BioCryst Pharmaceuticals (BCRX), received three grants on 2026-01-23: 2,582 shares issued in connection with BioCryst’s merger with Astria (conversion of 4,377 Astria shares), 12,272 restricted stock units (RSUs), and 26,684 stock options (a derivative grant). The merger-related exchange also included cash consideration of $8.55 per Astria share, which for Ms. Milne’s 4,377 Astria shares equals approximately $37,423.35 before taxes. These were awards/grants (not open-market purchases or sales).
Key Details
- Transaction date: 2026-01-23; Form 4 filed 2026-01-27 (filed within the typical 2-business-day window).
- Grants: 2,582 shares (merger conversion, footnote F1), 12,272 RSUs (footnote F2), 26,684 stock options (footnotes F3–F4). Total listed awards = 41,538 equity instruments.
- Cash from merger: Ms. Milne received ~$8.55 per Astria share converted (4,377 shares → ~ $37,423.35 before withholding).
- Vesting: RSUs vest in three equal annual installments starting 12 months after grant (F2). Options vest 1/36 per month over 3 years from grant (F4).
- Shares owned after transaction: not specified in the provided filing excerpt.
- Filing timeliness: No late filing flag noted.
Context
- The 2,582 shares were issued as part of the Astria merger consideration (partial stock + cash conversion), while the RSUs and options are routine automatic non-employee director compensation under BioCryst’s director policy.
- These are awards/grants (A); they do not represent an open-market purchase (bullish signal) or sale (liquidation). Grants reflect compensation and alignment with shareholders rather than an independent expression of trading sentiment.
Insider Transaction Report
Form 4
Milne Jill C.
Director
Transactions
- Award
Common Stock
[F1]2026-01-23+2,582→ 2,582 total - Award
Common Stock
[F2]2026-01-23+12,272→ 14,854 total - Award
Automatic Stock Option Grant
[F3][F4]2026-01-23+26,684→ 26,684 totalExercise: $6.79Exp: 2036-01-23→ Common Stock (26,684 underlying)
Footnotes (4)
- [F1]Received in exchange for 4,377 shares of Astria Therapeutics, Inc. ("Astria") common stock in connection with a merger (the "Merger"), pursuant to which Astria became a wholly owned subsidiary of BioCryst Pharmaceuticals, Inc. ("BioCryst"). Pursuant to the Merger, each share of Astria common stock (subject to certain inapplicable exceptions) was converted into the right to receive (i) 0.59 of a share of common stock of BioCryst and, if applicable, cash in lieu of fractional shares, and (ii) $8.55 in cash, without interest, subject to applicable withholding taxes. On the last trading day before the effective date of the Merger, the closing price of Astria's common stock was $12.58 per share, and the closing price of BioCryst's common stock was $6.75 per share.
- [F2]Automatic non-employee director grant of restricted stock units pursuant to the BioCryst Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest in three equal annual installments beginning on the twelve-month anniversary of the date of grant.
- [F3]Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.
- [F4]The option grant vests 1/36 per month over a 3-year period measured from the date of grant.
Signature
/s/ Alane P. Barnes, by power of attorney|2026-01-27